Gemtuzumab ozogamicin: is there room for salvage?
Publication
, Journal Article
Clarke, WT; Marks, PW
Published in: Blood
October 7, 2010
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Blood
DOI
EISSN
1528-0020
Publication Date
October 7, 2010
Volume
116
Issue
14
Start / End Page
2618 / 2619
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Leukemia, Myeloid, Acute
- Immunology
- Humans
- Gemtuzumab
- Clinical Trials as Topic
- Antineoplastic Agents
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
Citation
APA
Chicago
ICMJE
MLA
NLM
Clarke, W. T., & Marks, P. W. (2010). Gemtuzumab ozogamicin: is there room for salvage? Blood, 116(14), 2618–2619. https://doi.org/10.1182/blood-2010-08-300871
Clarke, W Thomas, and Peter W. Marks. “Gemtuzumab ozogamicin: is there room for salvage?” Blood 116, no. 14 (October 7, 2010): 2618–19. https://doi.org/10.1182/blood-2010-08-300871.
Clarke WT, Marks PW. Gemtuzumab ozogamicin: is there room for salvage? Blood. 2010 Oct 7;116(14):2618–9.
Clarke, W. Thomas, and Peter W. Marks. “Gemtuzumab ozogamicin: is there room for salvage?” Blood, vol. 116, no. 14, Oct. 2010, pp. 2618–19. Pubmed, doi:10.1182/blood-2010-08-300871.
Clarke WT, Marks PW. Gemtuzumab ozogamicin: is there room for salvage? Blood. 2010 Oct 7;116(14):2618–2619.
Published In
Blood
DOI
EISSN
1528-0020
Publication Date
October 7, 2010
Volume
116
Issue
14
Start / End Page
2618 / 2619
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Leukemia, Myeloid, Acute
- Immunology
- Humans
- Gemtuzumab
- Clinical Trials as Topic
- Antineoplastic Agents
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal